Rinvoq

Generic name: upadacitinib

Used for: Rheumatoid arthritis · Psoriatic arthritis · Eczema (atopic dermatitis) · Ulcerative colitis · Crohn’s disease · Arthritis of the spine (including ankylosing spondylitis) · Juvenile arthritis · Giant cell arteritis (inflamed blood vessels) · 7 more

How do you pay?

How to pay the least

Cash price

$6,880+ for 30 tablets

Pharmacies pay about this for Rinvoq; you’d pay more.

  1. Ask your pharmacy for Rinvoq’s cash price, and one or two other pharmacies too.
  2. Rinvoq’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify myAbbVie Assist. Our income guidelines are based on the size of your household and annual income. Or call 1-800-222-6885.

See if you qualify 

No generic is sold yet.

Compare every option

Question
Brand nameRinvoq
Authorized genericupadacitinib
Regular genericupadacitinib
What you’d pay
At least$6,880for 30 tablets; pharmacies pay this
Not soldThere isn’t one
Not soldNone sold yet
Same as Rinvoq?
The original
–
–

Brand nameThe maker’s card

RINVOQ Complete Savings Card

Savings card from AbbVie

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a month

The card takes up to $14,000 a year off your co-pay.

Sign up on rinvoq.com 

Or call 1-800-274-6867. See the offer on rinvoq.com

In the maker’s words

“If you have commercial insurance, you may be eligible to pay as little as $0 a month for your prescription with the RINVOQ Complete Savings Card.”

From the maker’s offer on rinvoq.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Rinvoq itself, from the same company, sold without the brand name, and usually for less. For now Rinvoq is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

No generic is sold yet. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

RINVOQ/RINVOQ LQ is a Janus kinase (JAK) inhibitor.

  • RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.
  • RINVOQ/RINVOQ LQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. Limitation s of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.
  • RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable. Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.
  • RINVOQ is indicated for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to one or more TNF blockers. If TNF blockers are clinically inadvisable, patients should have received at least one approved systemic therapy prior to use of RINVOQ. Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for UC, or with potent immunosuppressants such as azathioprine and cyclosporine.
  • RINVOQ is indicated for the treatment of adults with moderately to severely active Crohn’s disease (CD) who have had an inadequate response or intolerance to one or more TNF blockers. If TNF blockers are clinically inadvisable, patients should have received at least one approved systemic therapy prior to use of RINVOQ. Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for CD, or with potent immunosuppressants such as azathioprine and cyclosporine.
  • RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.
  • RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy. Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.
  • RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. Limitations of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.
  • RINVOQ is indicated for the treatment of adults with giant cell arteritis Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.

Source: the FDA label for Rinvoq (AbbVie Inc.), June 30, 2026. Full label on DailyMed 

Good to know

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/rinvoq/